ACIP Recommended Schedule MenB Routine Age Group Dosing Schedule Vaccine Recommendations Give two doses, at least one 10 through BEXSERO, High-Risk only month apart (0 and 1-6 month 18 Years Novartis schedule) Give two doses, at least one 19 or BEXSERO, High-Risk only month apart (0 and 1-6 month Older Novartis schedule) TRUMENBA, 10 through Give three doses High-Risk only 18 Years (0, 2, and 6 month schedule) Pfizer TRUMENBA, 19 Years Give three doses High-Risk only or Older (0, 2, and 6 month schedule) Pfizer Note: "Both MenB vaccines are approved for use in persons aged 10 through 25 however, because there are no theoretical differences in safety for persons aged >25 years compared with those aged 10 through 25 years, ACIP supported routine use of MenB vaccines in persons aged 10 years who are at ≥ increased risk for serogroup B meningococcal disease." Note: Use of MenB vaccines in persons aged 26 years or older would be an off-label use. MenB Permissive Age Group Dosing Schedule Vaccine Recommendations Give two doses, at least one 16 through BEXSERO, Other than High-Risk month apart (0 and 1-6 month 18 Years Novartis schedule) Give two doses, at least one 19 through BEXSERO, Other than High-Risk month apart (0 and 1-6 month 23 Years Novartis schedule) 16 through TRUMENBA, Give three doses Other than High-Risk 18 Years Pfizer (0, 2, and 6 month schedule) 19 through TRUMENBA, Give three doses Other than High-Risk 23 Pfizer (0, 2, and 6 month schedule) Note: ACIP recommended in October 2015 that a MenB vaccine series may be administered to adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years,
ACIP Recommended Schedule Age Group MenB Vaccine Routine Recommendations Dosing Schedule 10 through 18 Years BEXSERO, Novartis High-Risk only Give two doses, at least one month apart (0 and 1-6 month schedule) 19 or Older BEXSERO, Novartis High-Risk only Give two doses, at least one month apart (0 and 1-6 month schedule) 10 through 18 Years TRUMENBA, Pfizer High-Risk only Give three doses (0, 2, and 6 month schedule) 19 Years or Older TRUMENBA, Pfizer High-Risk only Give three doses (0, 2, and 6 month schedule) Note: "Both MenB vaccines are approved for use in persons aged 10 through 25 however, because there are no theoretical differences in safety for persons aged >25 years compared with those aged 10 through 25 years, ACIP supported routine use of MenB vaccines in persons aged ≥ 10 years who are at increased risk for serogroup B meningococcal disease." Note: Use of MenB vaccines in persons aged 26 years or older would be an off-label use. Age Group MenB Vaccine Permissive Recommendations Dosing Schedule 16 through 18 Years BEXSERO, Novartis Other than High-Risk Give two doses, at least one month apart (0 and 1-6 month schedule) 19 through 23 Years BEXSERO, Novartis Other than High-Risk Give two doses, at least one month apart (0 and 1-6 month schedule) 16 through 18 Years TRUMENBA, Pfizer Other than High-Risk Give three doses (0, 2, and 6 month schedule) 19 through 23 TRUMENBA, Pfizer Other than High-Risk Give three doses (0, 2, and 6 month schedule) Note: ACIP recommended in October 2015 that a MenB vaccine series may be administered to adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years,